Sign in

    George Goodman

    Research Analyst at Jericho Partners

    George Goodman is a Research Analyst at Jericho Partners, specializing in healthcare sector coverage with a particular focus on medical technology companies. He has covered Microbot Medical and participated in earnings call research, demonstrating engagement with company performance insights. Goodman’s professional track record includes analytical work at Jericho Partners, with coverage history confirmed for at least one public company. Details regarding his career timeline, previous firms, securities licenses, and professional credentials are not widely published, and no major performance metrics or recognitions are currently available.

    George Goodman's questions to Microbot Medical (MBOT) leadership

    George Goodman's questions to Microbot Medical (MBOT) leadership • Q2 2017

    Question

    George Goodman of Jericho Partners inquired about Microbot's strategy for its intellectual property portfolio, specifically the potential for partnering with larger companies. He also asked about future financing needs, the expected timeline for FDA approval of the Self-Cleaning Shunt, and the current competitive landscape.

    Answer

    Harel Gadot, CEO, President and Chairman, explained that while the company is exploring partnerships, its unique core capabilities are a key asset that larger firms seek. He confirmed the recent financing provides a 24-30 month cash runway and that they will continue to explore non-dilutive grants. Regarding the FDA, Mr. Gadot detailed the 510(k) pathway, targeting a late 2018 submission, which could result in a 3-6 month review. He characterized the market as a "blue ocean," with no direct competitors for a self-cleaning shunt.

    Ask Fintool Equity Research AI